GlassScriptPhysician profile
Bharati Chittineni
NPI 1275525495
$1,718.94
in general payments reported to CMS, 2019-2025
25 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $123 · 2022: $40.10 · 2023: $193 · 2024: $225 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $565 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $565.10 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $467.44 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $208.09 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $140.68 | 2019-2024 | |
| Pfizer INC. | $111.32 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $91.29 | 2019-2025 | |
| Organon LLC | $84.77 | 2025 | Vtama, Nexplanon |
| Galderma Laboratories, L.P. | $80.69 | 2019-2024 | |
| Amgen INC. | $62.48 | 2020-2025 | Otezla |
| Dermira, INC. | $54.11 | 2019 | |
| Janssen Biotech, INC. | $52.08 | 2019-2020 | |
| Celgene Corporation | $52.02 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $48.00 | 2019-2024 | Libtayo |
| Ucb, INC. | $46.09 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $34.96 | 2019-2025 | Ebglyss |
| Smith+Nephew, INC. | $22.43 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $20.00 | 2024 | Vtama |
| Almirall LLC | $19.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.34 | 2024 | Sotyktu |
| Vyne Pharmaceuticals INC. | $17.27 | 2020 | |
| Biofrontera INC. | $17.17 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Genzyme Corporation | $15.73 | 2022 | |
| Arcutis Biotherapeutics, INC. | $14.35 | 2025 | Zoryve |
| Medtronic, INC. | $14.17 | 2023 | V-Loc 180 |
| Encore Dermatology INC. | $14.02 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bharati Chittineni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.